Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II percutaneous hepatic perfusion with melphalan for unresectable liver metastases from uveal melanoma
NL-OMON21170Phase 2Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of melphalan in intraocular melanoma and hepatic metastasis, sponsored by Leiden University Medical Center. Primary endpoints: Overall response rate and Conversion to curative resection. Started Feb 2014; status: active, not recruiting.
02
Drugs
melphalan
03
Conditions
intraocular melanomahepatic metastasis
Beyond the preview
Go deeper on NL-OMON21170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21170.